1-13 of 13
Sandrine Macé
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Robert Z. Orlowski, Meletios-Athanasios Dimopoulos, Xavier Leleu, Zhuogang Liu, Tadao Ishida, Roman Hajek, Ivan Špička, Joanna Romejko-Jarosinska, Vladimir I. Vorobyev, Britta Besemer, Sevgi Beşışık, Pawel Robak, Hartmut Goldschmidt, Thomas Martin, Mohamad Mohty, Sandrine Macé, Ercem Kodas, Christina Tekle, Andrea Shafer, Philippe Moreau
Journal: Blood
Blood (2024) 144 (Supplement 1): 770.
https://doi.org/10.1182/blood-2024-203818
Published: 2024
Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Enrique M Ocio, Aurore Perrot, Pierre Bories, Jesús F. San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Song-Yau Wang, Sara Bringhen, Maria-Victoria Mateos, Paula Rodríguez-Otero, Stefania Oliva, Axel Nogai, Bruno Paiva, Yi Li, Eric Le Bras, Sandrine Macé, Ercem Kodas, Helgi Van de Velde, Philippe Moreau
Journal: Blood
Blood (2024) 144 (Supplement 1): 1976.
https://doi.org/10.1182/blood-2024-200135
Published: 2024
Journal Articles

Blood-Based Mass Spectrometry MRD Tracking (M-InSight) in Multiple Myeloma Patients from Clinical Trial NCT02513186

Luciano Di Stefano, Zarouki Mouktadi, Victor Vimard, Sarah Moreau, Sandrine Mace, Zandra K. Klippel, Vincent Bonifay, Caroline Rougé Dubroc, Pierre Sonigo
Journal: Blood
Blood (2023) 142 (Supplement 1): 3360.
https://doi.org/10.1182/blood-2023-179382
Published: 2023
Journal Articles

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Maria-Victoria Mateos, Paula Rodriguez Otero, Youngil Koh, Joaquin Martinez-Lopez, Gurdeep Parmar, H. Miles Prince, Hang Quach, Paz Ribas, Emil Hermansen, Vania T.M. Hungria, Sevgi Kalayoglu Besisik, Jin Seok Kim, Xavier Leleu, Valdas Pečeliūnas, Fredrik Schjesvold, Omur G. Sevindik, Tatiana Lavrova, Franck Dubin, Christine Devisme, Lucie Lepine, Sandrine Macé, Mony Morisse, Irene Ghobrial
Journal: Blood
Blood (2022) 140 (Supplement 1): 7317–7319.
https://doi.org/10.1182/blood-2022-157302
Published: 2022
Journal Articles

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Nobuhiro Tsukada, Kazutaka Sunami, Pierre Bories, Sumit Madan, Dorothee Semiond, Disa Yu, Sandrine Macé, Florence Suzan, Philippe Moreau
Journal: Blood
Blood (2022) 140 (Supplement 1): 4412–4414.
https://doi.org/10.1182/blood-2022-166840
Published: 2022
Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment

Marcelo Capra, Thomas Martin, Philippe Moreau, Gracia Martinez, Albert Oriol, Youngil Koh, Hang Quach, Kwee Yong, Andreea Rawlings, Christina Tekle, Sandrine Macé, Marie-Laure Risse, Ivan Spicka
Journal: Blood
Blood (2022) 140 (Supplement 1): 7138–7140.
https://doi.org/10.1182/blood-2022-162731
Published: 2022
Journal Articles

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

Paul G. Richardson, Aurore Perrot, Jesús San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Jeffrey SY Huang, Jiri Minarik, Michele Cavo, H. Miles Prince, Sandrine Macé, Laure Malinge, Franck Dubin, Mony Morisse, Kenneth C. Anderson
Journal: Blood
Blood (2022) 140 (Supplement 1): 608–610.
https://doi.org/10.1182/blood-2022-159710
Published: 2022
Journal Articles

A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma

Philippe Moreau, Gurdeep Parmar, Miles Prince, Enrique Ocio, Chatchada Karanes, Sumit Madan, Albert Oriol, Pierre Bories, Michel Delforge, Nashat Gabrail, Dorothee Semiond, Nan Jia, Sandrine Macé, Florence Suzan, Helgi van de Velde, Hang Quach
Journal: Blood
Blood (2021) 138 (Supplement 1): 2744.
https://doi.org/10.1182/blood-2021-147136
Published: 2021
Journal Articles

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo, Craig Cole, Cristina Gasparetto, Vania Hungria, Matthew Jenner, Vladimir Vorobyev, Eduardo Yanez Ruiz, Jian Y. Yin, Rao Saleem, Maeva Hellet, Sandrine Macé, Bruno Paiva, Ravi Vij
Journal: Blood
Blood (2021) 137 (9): 1154–1165.
https://doi.org/10.1182/blood.2020008209
Published: 2021
Includes: Supplemental data
Journal Articles

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Thomas Martin, MD, Joseph Mikhael, MD FRCPC, MD, Roman Hajek, MD, Kihyun Kim, MD PhD, Kenshi Suzuki, MD PhD, Cyrille Hulin, MD, Mamta Garg, MD FRCP, FRCPath, Hang Quach, MDFRACP,FRCPA,MBBS, Hanlon Sia, Anup George, Tatiana Konstantinova, MD PhD, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, MD PhD, Philippe Moreau, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-137681
Published: 2020
Journal Articles

Development of a Hydrashift 2/4 Isatuximab Assay to Mitigate Interference with Monoclonal Protein Detection on Immunofixation Electrophoresis in Vitro Diagnostic Tests in Multiple Myeloma

Greg Finn, PhD, Sandrine Macé, Ruiyin Chu, Helgi van de Velde, MD PhD, Samia Menad, Marie-Thérèse Melki, PhD, Georges Nouadje
Journal: Blood
Blood (2020) 136 (Supplement 1): 15.
https://doi.org/10.1182/blood-2020-136613
Published: 2020
Journal Articles

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Paul G. Richardson, MD, Joseph Mikhael, MD FRCPC, MD, Thierry Facon, MD, William I. Bensinger, Sandrine Macé, Marielle Chiron, Helgi van de Velde, MD PhD, Frank Campana, MD, Li Liu, Michel Attal, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3179.
https://doi.org/10.1182/blood-2019-128071
Published: 2019
Journal Articles

Evaluating Isatuximab Interference with Monoclonal Protein Detection By Immuno-Capture and Liquid Chromatography Coupled to High Resolution Mass Spectrometry in the Pivotal Phase 3 Multiple Myeloma Trial, Icaria-MM

Greg Finn, PhD, Sandrine Macé, Frank Campana, MD, Solenn Le-Guennec, Stephané Muccio, Alexandra Tavernier, Marie-Claude Rouchon, Alain Roccon, Shujia Dai, Valérie Boutet, Dominique Mouret, Béatrice Pradeilles, Sébastien Hugla, Graziella Engelvin, Deborah DiNoto, Helgi van de Velde, MD PhD, Olivier Fedeli
Journal: Blood
Blood (2019) 134 (Supplement_1): 3143.
https://doi.org/10.1182/blood-2019-129963
Published: 2019